Bacillus Calmette-Guérin immunotherapy for genitourinary cancer

BJU International

Volumn 112, Issue 3, 2013, Pages 288-297

  Gandhi, Nilay M ^a   Morales, Alvaro ^b   Lamm, Donald L ^c  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b QUEEN S UNIVERSITY   (Canada)

^c UNIVERSITY OF ARIZONA   (United States)

Author keywords

BCG; bladder cancer; immunotherapy; maintenance; NMIBC; non muscle invasive bladder cancer

Indexed keywords

BCG VACCINE; DOXORUBICIN; EPIRUBICIN; GEMCITABINE; INTERFERON; MITOMYCIN; SUNITINIB; TEMSIROLIMUS; THIOTEPA;

CANCER CHEMOTHERAPY; CANCER GRADING; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER SURGERY; CARCINOMA IN SITU; CRYOTHERAPY; DRUG EFFICACY; DRUG FEVER; DRUG HYPERSENSITIVITY; DYSURIA; FOLLOW UP; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; KIDNEY CANCER; MAINTENANCE THERAPY; NON MUSCLE INVASIVE BLADDER CANCER; NONHUMAN; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; REVIEW; SEPSIS; TUBERCULOSIS; UROGENITAL TRACT CANCER; VACCINATION;

BCG; BLADDER CANCER; IMMUNOTHERAPY; MAINTENANCE; NMIBC; NON-MUSCLE INVASIVE BLADDER CANCER;

ADJUVANTS, IMMUNOLOGIC; BCG VACCINE; HUMANS; IMMUNOTHERAPY; UROGENITAL NEOPLASMS;

EID: 84879887890     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2012.11754.x     Document Type: Review

References (74)

1. Lamm D,. Bacillus Calmette-Guerin immunotherapy of Genitourinary Cancer. In, Orentas R, Hodge J, Johnson B, eds, Cancer Vaccines and Tumor Immunity, Chapt. 3. Hoboken, NJ: John Wiley & Sons, 2008: 29-42
2. Crispen R,. History of BCG and its substrains. In, Liss A, ed., EORTC Genitourinary Group Monograph 6: BCG in Superficial Bladder Cancer, New York: John Wiley and Sons, 1989: 35-50
3. Skamene E,. The BCG gene story. Immunobiology 1994; 191: 451-460
4. Gheorgiu M,. Antituberculosis BCG vaccine: lessons from the past. In, Plotkin SA, ed., History of Vaccine Development, New York: Springer, 2011: 47-56
5. Calmette A, Bocquet A, Negre L,. Contribution a l'etude du bacilli tuberculuex bilie. Ann Inst Pasteur 1921; 9: 561-570
6. Guerin C,. The history of BCG. In, Rosenthal SR, ed., BCG Vaccine: Tuberculosis-Cancer, Littleton, MA: PSG Publishing Co. Inc., 1980: 35
7. Calmette A, Guerin C, Negre L, Bocquet A,. Premunition des nouveau-nes contre la tuberculose par le vaccine BCG (1921-1926). Ann Inst Pasteur 1926; 2: 89-120
8. Lange B,. Nouvelles recherché sur les causes des accidents de Lubeck. Rev Tuberc Extrait 1931; XII: 1142-1170
9. Coley WB,. The treatment of malignant tumors by repeated inoculations of Erysipelas, with a report of ten original cases. Am J Med Sci 1893; 105: 487-511
10. Mastrangelo G, Fadda E, Milan G,. Cancer increased after a reduction of infections in the first half of this century in Italy: etiologic and preventive implications. Eur J Epidemiol 1998; 14: 749-754
11. Pearl R,. Cancer and tuberculosis. Am J Hygeine 1929; 9: 97
12. Holmgren I,. Employment of B.C.G., especially in intravenous injection. Acta Med Scand 1936; 90: 350-361
13. Rosenthal SR,. Focal and general tissue responses to an avirulent tubercle bacillus (BCG) intracardiac route. Arch Path 1936; 22: 348
14. Old LJ, Clarke DA, Benacerraf B,. Effect of bacillus Calmette-Guerin infection on transplanted tumours in the mouse. Nature 1959; 184: 291
15. Rosenthal SR,. BCG in Cancer and Leukemia. In, Rosenthal SR, ed., BCG Vaccine: Tuberculosis-Cancer, Littleton, MA: PSG Publishing Co. Inc., 1980: 295
16. Morton DL,. BCG immunotherapy of malignant melanoma: summary of a seven-year experience. Ann Surg 1974; 180: 635-641
17. Coe JE, Feldman JD,. Extracutaneous delayed hypersensitivity, particularly in the guinea-pig bladder. Immunology 1996; 10: 127-136
18. Silverstein MJ, DeKernion J, Morton DL,. Malignant melanoma metastatic to the bladder. Regression following intratumor injection of BCG vaccine. JAMA 1974; 229: 688
19. Lamm DL, Harris SC, Gittes RF,. Bacillus Calmette-Guerin and dinitrochlorobenzene immunotherapy of chemically induced bladder tumors. Invest Urol 1977; 14: 369-372
20. Herr HW, Morales A,. History of bacillus Calmette-Guerin and bladder cancer: an immunotherapy success story. J Urol 2008; 179: 53-56
21. Morales A, Eidinger D, Bruce AW,. Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol 1976; 116: 180-183
22. Lamm DL, Thor DE, Harris SC, Reyna JA, Stogdill VD, Radwin HM,. Bacillus Calmette-Guerin immunotherapy of superficial bladder cancer. J Urol 1974; 124: 38-40
23. Lamm DL,. BCG immunotherapy for superficial bladder cancer. In, Ratliff TL, Catalona WJ, eds, Genitourinary Cancer, Boston, MA: Marinus Nijhoff, 1987: 205
24. Pinsky CM, Camacho FJ, Kerr D, et al. Intravesical administration of bacillus Calmette-Guerin in patients with recurrent superficial carcinoma of the urinary bladder: report of a prospective, randomized trial. Cancer Treat Rep 1985; 69: 47-53
25. Herr HW,. Extravesical tumor relapse in patients with superficial bladder tumors. J Clin Oncol 1998; 16: 1099-1102
26. Ratliff TL, Kavoussi LR, Catalona WJ,. Role of fibronectin in intravesical BCG therapy for superficial bladder cancer. J Urol 1988; 139: 410-414
27. Kuroda K, Brown EJ, Telle WB, Russell DG, Ratliff TL,. Characterization of the internalization of bacillus Calmette-Guerin by human bladder tumor cells. J Clin Invest 1993; 91: 69-76
28. Bevers RF, de Boer EC, Kurth KH, Schamhart DH,. BCG-induced interleukin-6 upregulation and BCG internalization in well and poorly differentiated human bladder cancer cell lines. Eur Cytokine Netw 1998; 9: 181-186
29. Lamm DL, Thor DE, Stogdill VD, Radwin HM,. Bladder cancer immunotherapy. J Urol 1982; 128: 931-935
30. Lattime EC, Gomella LG, McCue PA,. Murine bladder carcinoma cells present antigen to BCG-specific CD4+ T-cell. Cancer Res 1992; 52: 4286-4290
31. Bohle A, Gerdes J, Ulmer AJ, Hofstetter AG, Flad HD,. Effects of local bacillus Calmetter-Guerin therapy in patients with bladder carcinoma on immunocompetent cells of the bladder wall. J Urol 1990; 144: 53-58
32. Prescott S, Hargreave TB, Chisholm GD, Smyth JF,. Intravesical Evans strain BCG therapy: quantitative immunohistochemical analysis of the immune response within the bladder wall. J Urol 1992; 147: 1636-1642
33. Ratliff TL, Ritchey JK, Yuan JJ, Andriole GL, Catalona WJ,. T-cell subsets required for intravesical BCG immunotherapy for bladder cancer. J Urol 1993; 150: 1018-1023
34. Jackson AM, Alexandroff AB, Kelly RW, et al. Changes in urinary cytokines and soluble intercellular adhesion molecule-1 (ICAM-1) in bladder cancer patients after bacillus Calmette-Guerin (BCG) immunotherapy. Clin Exp Immunol 1995; 99: 369-375
35. Ludwig AT, Moore JM, Luo Y, et al. Tumor necrosis factor-related apoptosis-inducing ligand: a novel mechanism for Bacillus Calmette-Guerin- induced antitumor activity. Cancer Res 2004; 64: 3386-3390
36. Morales A,. Treatment of carcinoma in situ of the bladder with BCG: a phase II trial. Cancer Immunol Immunother 1980; 9: 69-72
37. Lamm DL, Blumenstein BA, Crawford ED, et al. A randomized trial of intravesical doxorubicin and immunotherapy with Bacille Calmette-Guérin for transitional cell carcinoma of the bladder. New Engl J Med 1991; 325: 1205-1209
38. Lamm DL,. Preventing progression and improving survival with BCG maintenance. Eur Urol 2000; 37 (Suppl. 1): 9-15
39. Lamm DL, Blumenstein BA, Crissman JD, et al. Maintenance bacillus Calmette-Guerin immunoterapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol 2000; 163: 1124-1129
40. Lamm DL,. Carcinoma in situ. Urol Clin North Am 1992; 19: 499-508
41. Lamm DL,. Bacillus Calmette-Guerin immunotherapy. J Urol 1987; 138: 391-392
42. Hudson MA, Ratliff TL, Gillen DP, Haaff EO, Dresner SM, Catalona WJ,. Single course versus maintenance bacillus Calmette-Guerin therapy for superficial bladder tumors: a prospective, randomized trial. J Urol 1987; 138: 295-298
43. Badalament RA, Herr HW, Wong GY, et al. A prospective randomized trial of maintenance versus nonmaintenance intravesical bacillus Calmette-Guerin therapy of superficial bladder cancer. J Clin Oncol 1987; 5: 441-449
44. Herr HW, Dalbagni G, Donat SM,. Bacillus Calmette-Guerin without maintanence therapy for high-risk non-muscle invasive bladder cancer. Eur Urol 2011; 60: 32-36
45. Palou J, Laguna P, Millan-Rodriguez F, Hall RR, Salvador-Bayarri J, Vicente-Rodriguez J,. Control group and maintenance treatment with bacillus Calmette-Guerin for carcinoma in situ and/or high grade bladder tumors. J Urol 2001; 165: 1488-1491
46. Sylvester RJ, van der Meijden AP, Intravesical LDL,. bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 2002; 168: 1964-1970
47. Reichert DF, Lamm DL,. Long term protection in bladder cancer following intralesional immunotherapy. J Urol 1984; 132: 570-573
48. Bohle A, Jocham D, Bock PR,. Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol 2003; 169: 90-95
49. Malmström PU, Sylvester RJ, Crawford DE, et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus Bacillus Calmette-Guerin for non-muscle-invasive bladder cancer. Eur Urol 2009; 56: 247-256
50. Sylvester RJ, Brausi MA, Kirkels WJ, et al. Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder. Eur Urol 2010; 57: 766-773
51. Brausi M, Oddens J, Sylvester R, et al. Bacillus Calmette-Guerin: one third dose versus full dose and one year versus three years of maintenance. Final results of EORTC GU Cancers Group randomized trial 30962 in non muscle invasive bladder cancer. AUA. 2012. abstract 1665. Available at: http://www.aua2012.org/abstracts/process.cfm?title=Bladder+Cancer: +Superficial&searchType=title. Accessed November 2012
52. Lamm DL,. Efficacy and safety of bacille Calmette-Guerin immunotherapy in superficial bladder cancer. Clin Infect Dis 2000; 31 (Suppl. 3): S86-90
53. Luftenegger W, Ackermann DK, Futterlieb A, et al. Intravesical versus intravesical plus intradermal bacillus Calmette-Guerin: a prospective randomized study in patients with recurrent superficial bladder tumors. J Urol 1996; 155: 483-487
54. Colombel M, Saint F, Chopin D, Nicolas L, Rischmann P,. The effect of ofloxacin on Bacillus Calmette-Guerin induced toxicity in patients with superficial bladder cancer: results of a randomized, prospective, double-blind, placebo controlled, multicenter study. J Urol 2006; 176: 935-939
55. Vegt PD, van der Meijden AP, Sylvester R, et al. EORTC Genito-Urinary Group: does isoniazid reduce side-effects of intravesical Bacillus Calmette-Guerin therapy in superficial bladder cancer? Interim results of Cancer protocol 30911. J Urol 1997; 157: 1246-1249
56. Lamm DL, Torti FM,. Bladder cancer, 1996. CA Cancer J Clin 1996; 46: 93-112
57. American Urological Association. Guidelines for the Management of Non-Muscle Invasive Bladder Cancer (Stages Ta, T1, and Tis): 2010 Update. Linthicum, MD: AUA, 2010
58. Lamm DL, Blumenstein BA, Crawford ED, et al. Randomized intergroup comparison of bacillus Calmette-Guérin immunotherapy and mitomycin C chemotherapy prophylaxis in superficial transitional cell carcinoma of the bladder, A Southwest Oncology Group study. Urol Oncol 1995; 1: 119-126
59. Shelley MD, Court JB, Kynaston H, Wilt TJ, Coles B, Mason M,. Intravesical Bacillus Calmette-Guerin versus mitomycin C for Ta and T1 bladder cancer. Cochrane Database Syst Rev 2003; (3) CD003231
60. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology: Bladder Cancer Including Upper Tract Tumours and Urothelial Carcinoma of the Prostate. Version 1. Jenkintown, PA: NCCN, 2012
61. Di Stasi SM, Giannantoni A, Giurioli A, et al. Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial. Lancet Oncol 2006; 7: 43-51
62. Morales A, Wilson JL, Pater JL, Loeb M,. Cytoreductive surgery and systemic bacillus Calmette-Guerin therapy in metastatic renal cancer. J Urol 1982; 127: 230-235
63. Dagnone AJ, Young I, Morales A,. Metastatic renal cell carcinoma regression after nephrectomy and BCG immunotherapy. Can J Urol 1999; 6: 749-750
64. Mavrichev AS, Grigorovich NA, Sukonko OG,. Rovbut' II. [The late results of the combined treatment of kidney cancer patients]. Urol Nefrol (Mosk) 1990; 5: 13-16
65. Wirth MP,. Immunotherapy for metastatic renal cell carcinoma. Urol Clin North Am 1993; 20: 283-295
66. Merrin C, Han T, Klein E, Wajsman Z, Murphy GP,. Immunotherapy of prostatic carcinoma with bacillus Calmette-Guerin. Cancer Chemother Rep 1975; 59: 157-163
67. Robinson MR, Rigby CC, Pugh RC, Dumonde DC,. Prostate carcinoma: intratumor BCG immunotherapy. Natl Cancer Inst Monogr 1978; 49: 351-353
68. Pollard M, Luckert PH,. Immunotherapy by BCG against prostate adenocarcinomas in anatomical compartments. Anticancer Res 1994; 14: 2691-2694
69. Lubaroff DM, Reynolds CW, Canfield L, McElligott D, Feldbush T,. Immunologic aspects of the prostate. Prostate 1981; 2: 233-248
70. Morales A, Nickel JC, Manley PN,. Induction of controlled prostatic tissue necrosis by bacille Calmette-Guerin derivatives. Urol Res 1991; 19: 35-38
71. Guinan PD, John T, Nagale V, Ablin RJ,. BCG adjuvant immunotherapy in carcinoma of the prostate: an interim report. Allergol Immunopathol (Madr) 1978; 6: 293-296
72. Guinan PD, John T, Baumgartner G, Sundar B, Ablin RJ,. Adjuvant immunotherapy (BCG) in stage D prostate cancer. Am J Clin Oncol 1982; 5: 65-68
73. Siegel R, Naishadham D, Jemal A,. Cancer statistics, 2012. CA Cancer J Clin 2012; 62: 10-29
74. Witjes JA, Palou J, Soloway M, et al. Current practice gaps in the use of Bacillus Calmette-Guerin (BCG) maintenance: Results of the international individual patient data survey (IPDS). J Urol 2012; 187: e219